Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Sells $92,550.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora sold 15,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $6.17, for a total transaction of $92,550.00. Following the completion of the transaction, the chief financial officer now owns 1,377,756 shares in the company, valued at approximately $8,500,754.52. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Michael Secora also recently made the following trade(s):

• On Tuesday, August 13th, Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.35, for a total transaction of $95,250.00.
• On Tuesday, July 9th, Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.32, for a total transaction of $109,800.00.

Recursion Pharmaceuticals Price Performance

Shares of RXRX stock traded up $0.05 on Thursday, reaching $6.50. The company’s stock had a trading volume of 3,440,323 shares, compared to its average volume of 5,905,548. Recursion Pharmaceuticals, Inc. has a 1 year low of $4.97 and a 1 year high of $15.74. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -4.06 and a beta of 0.82. The stock’s fifty day simple moving average is $7.25 and its 200-day simple moving average is $8.66. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The business had revenue of $14.42 million for the quarter, compared to the consensus estimate of $11.96 million. During the same quarter last year, the business posted ($0.38) earnings per share. The firm’s revenue for the quarter was up 30.9% compared to the same quarter last year. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in RXRX. Benjamin F. Edwards & Company Inc. purchased a new position in Recursion Pharmaceuticals in the first quarter valued at about $26,000. National Bank of Canada FI grew its stake in Recursion Pharmaceuticals by 90.9% in the fourth quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after purchasing an additional 1,500 shares during the last quarter. GAMMA Investing LLC grew its stake in Recursion Pharmaceuticals by 1,588.4% in the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after purchasing an additional 6,036 shares during the last quarter. Amalgamated Bank grew its stake in Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after purchasing an additional 2,459 shares during the last quarter. Finally, Midwest Financial Group LLC purchased a new position in Recursion Pharmaceuticals in the second quarter valued at about $90,000. 89.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

RXRX has been the subject of a number of research analyst reports. KeyCorp cut their price objective on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Leerink Partners cut their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Jefferies Financial Group cut their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Finally, Needham & Company LLC cut their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $9.40.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.